Corifollitropin alfa application in art programs in women over 40 years

Abstract

Purpose of the study is evaluation of clinical outcomes, embryological characteristics, pharmacoeconomic aspects of corifollitropina alpha application in the ART programs, conducted in patients older than 40 years at the expense of mandatory health insurance funds (compulsory medical insurance).40 ART programs at the expense of the compulsary medical insurance (OMS) were analyzed (20 patients whose controlled ovarian stimulation - COS was carried out using follitropinalfa, 20 patients, whose COS was conducted using corifollitropina alpha). We analyzed the data of the anamnesis, clinical and gynecological examinations, hormonal status, ultrasound scans, folliculogenesis parameters in stimulation protocol, number and quality of the oocytes, embryos. The effectiveness of corifollitropina alfa and follitropinalfa in patients older than 40 years is the same. Implementation of the ART programs using corifollitropina alpha is more pharmaeconomicly reasonable and saves budget money.

Keywords

• assisted reproductive technology
• age
• compulsory health insurance
• corifollitropin alpha